The Data
/
Stocks
/ TFX
Equity · Healthcare
TFX
NYSE
Teleflex Incorporated
$134.68
−0.24% vs prior close
Finazon · prior-day close, indicative (IEX-derived, not the official close)
1D
1M
3M
1Y
5Y
All
Price · Chart
This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers. We hold too few licensed daily closes of our own for TFX to draw a line in its place.
Interactive TFX price chart by TradingView (requires JavaScript).
Market cap
$5.7B
52-week range
$100 – $140.91
Avg volume
113.9K
as of Jul 17, 2026
About Teleflex Incorporated
Teleflex Incorporated is a global provider of medical technology products, primarily designing, developing, manufacturing, and supplying single-use medical devices for hospitals and healthcare providers. Its products are used in diagnostic and therapeutic procedures in critical care and surgical applications and are marketed worldwide through direct sales and distributors. The company has major manufacturing operations in the Czech Republic, Malaysia, Mexico, and the United States. In December 2025, Teleflex announced definitive agreements to sell its Acute Care, Interventional Urology, and OEM businesses, with these transactions expected to close in the second half of 2026.
Company
Founded
1943
Headquarters
Wayne
Exchange
NYSE
Sector
Healthcare
Class
Equity
Insiders Form 4
Filings 5 sets
TFX insider trades
SEC Form 4 · last 90 days · newest Form 4 filing 8 Sep 2026
Open-market buys
0
Open-market sells
0
Non-trade filings
1
Compensation mechanics
Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.
Date
Insider
Type
Shares
Value
08 Sep 2026
Salmon Sean
Director
Award
674
TFX reported financials
SEC EDGAR XBRL
SEC EDGAR
TFX reported revenue of $2.0B for the fiscal year ended 31 Dec 2025. Net income over the same period was −$905.6M.
Figure
Reported
Period
Revenue
$2.0B
31 Dec 2025
fiscal year
Net income
−$905.6M
31 Dec 2025
fiscal year
Diluted EPS
−$20.25
31 Dec 2025
fiscal year
Total assets
$6.8B
30 Jun 2026
at period end
Total equity
$2.9B
30 Jun 2026
at period end
TFX earnings
SEC EDGAR
Date
Period
EPS
Revenue
30 Jun 2026
Q2 2026
$2.28
$570M
31 Mar 2026
Q1 2026
−$0.18
$548M
31 Dec 2025
FY 2025
−$16.15
$569M
28 Sep 2025
FY 2025
−$9.24
$567M
29 Jun 2025
FY 2025
$2.77
$443M
30 Mar 2025
Q1 2025
$2.07
$414M
Next report no date announced in SEC filings yet
Reported figures & scheduled dates · SEC EDGAR filings
9 of the 45 institutional funds we track reported a TFX position for the quarter ended 30 Jun 2026 — a combined $596.3M; the latest of those filings landed 02 Sep 2026.
TFX fails-to-deliver
SEC CNS data
SEC
On 24 Sep 2026, 1 shares of TFX failed to deliver (about $122).
Settlement date
Shares failed
Notional
% of shares out
24 Sep 2026
1
$122
<0.001%
16 Sep 2026
8,370
$1.1M
0.020%
14 Sep 2026
220
$29K
0.001%
09 Sep 2026
170
$23K
<0.001%
08 Sep 2026
67
$9K
<0.001%
The most recent congressional trade disclosed in TFX is a sale by Lisa C. McClain (house, MI), dated 22 Jul 2025.
Date
Member
Type
Amount
22 Jul 2025
filed 13 Aug 2025
Lisa C. McClain
house · Republican–MI
Sale
$1K–$15K
16 Jul 2025
filed 13 Aug 2025
Lisa C. McClain
house · Republican–MI
Purchase
$1K–$15K
25 Feb 2025
filed 27 Mar 2025
Robert P. Bresnahan, Jr.
house · Republican–PA
Sale
$1K–$15K
12 Jul 2023
filed 13 Aug 2023
Daniel S. Goldman
house · Democrat–NY
Sale
$15K–$50K
30 Nov 2022
filed 29 Dec 2022
Susie Lee
house · Democrat–NV
Sale
$1K–$15K
16 Dec 2020
filed 11 Jan 2021
Susie Lee
house · Democrat–NV
Purchase
$1K–$15K
08 Dec 2020
filed 11 Jan 2021
Susie Lee
house · Democrat–NV
Purchase
$1K–$15K
28 Apr 2020
filed 15 Jun 2020
Susie Lee
house · Democrat–NV
Sale
$1K–$15K
Sources
Finazon prior-day close, indicative (IEX-derived, not the official close)
TradingView the price chart widget, drawn by TradingView from their own data
SEC EDGAR SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
SEC EDGAR SEC EDGAR 13F filings
SEC SEC fails-to-deliver (CNS) data
House disclosures U.S. House of Representatives financial disclosures
SEC EDGAR Valuation computed from SEC EDGAR filings